U.S. markets closed
  • S&P Futures

    4,522.25
    +13.75 (+0.30%)
     
  • Dow Futures

    34,113.00
    +111.00 (+0.33%)
     
  • Nasdaq Futures

    15,925.75
    +56.00 (+0.35%)
     
  • Russell 2000 Futures

    2,154.50
    +8.20 (+0.38%)
     
  • Crude Oil

    65.88
    +0.31 (+0.47%)
     
  • Gold

    1,782.30
    -2.00 (-0.11%)
     
  • Silver

    22.43
    +0.09 (+0.41%)
     
  • EUR/USD

    1.1328
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.4340
    -0.0090 (-0.62%)
     
  • Vix

    31.12
    +3.93 (+14.45%)
     
  • GBP/USD

    1.3283
    +0.0005 (+0.04%)
     
  • USD/JPY

    112.9330
    +0.1530 (+0.14%)
     
  • BTC-USD

    57,206.43
    +109.56 (+0.19%)
     
  • CMC Crypto 200

    1,453.99
    -15.09 (-1.03%)
     
  • FTSE 100

    7,168.68
    +109.23 (+1.55%)
     
  • Nikkei 225

    27,812.30
    -123.32 (-0.44%)
     

Opiant Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SANTA MONICA, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, will present at the Jefferies Virtual Healthcare Conference, from 3:30-3:55pm ET on Thursday, June 3, 2021. Opiant will also host 1x1 investor meetings during the conference.

A live webcast of the presentation will be available under ‘Events & Presentations’ in the Investors section of the Opiant website: www.opiant.com. A replay of the webcast will be available for 30 days following the conclusion of the live presentation broadcast.

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.

For more information visit: www.opiant.com.

Investor Relations Contact:

Ben Atkins
VP of Corporate Communications and Investor Relations
Batkins@opiant.com
(310) 598-5410